Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype

American Journal of Gastroenterology

Volumn 104, Issue 6, 2009, Pages 1426-1434

  Seow, Cynthia H ^a   Stempak, Joanne M ^a   Xu, Wei ^b   Lan, Hui ^b   Griffiths, Anne M ^c   Greenberg, Gordon R ^a   Steinhart, A Hillary ^a   Dotan, Nir ^d   Silverberg, Mark S ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d Glycominds Ltd   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CARBOHYDRATE; CHITIN; CHITIN ANTIBODY; CHITOBIOSIDE ANTIBODY; GLYCAN DERIVATIVE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LAMINARAN; LAMINARIBIOSIDE ANTIBODY; LAMINARIN ANTIBODY; MANNOBIOSIDE ANTIBODY; PERINUCLEAR ATYPICAL NEUTROPHIL CYTOPLASMIC ANTIBODY; POLYSACCHARIDE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANUS DISEASE; ARTICLE; CELL WALL; CHILD; CONTROLLED STUDY; CROHN DISEASE; ENTERITIS; FEMALE; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PERIANAL DISEASE; PHENOTYPE; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; CHILD; CHILD, PRESCHOOL; COLITIS, ULCERATIVE; CROHN DISEASE; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOGLOBULIN A; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PHENOTYPE; POLYSACCHARIDES; ROC CURVE; YOUNG ADULT;

EID: 66949132914     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.79     Document Type: Article

References (27)

1. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology . Lancet 2007 ; 369 : 1627-40.
2. De Hertogh G, Aerssens J, Geboes KP et al. Evidence for the involvement of infectious agents in the pathogenesis of Crohn's disease . World J Gastroenterol 2008;14:845-52.
3. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427-34.
4. Targan SR, Landers CJ, Yang H et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease . Gastroenterology 2005 ; 128 : 2020-8.
5. Papp M, Altorjay I, Dotan N et al. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort . Am J Gastroenterol 2008; 103: 665 - 81.
6. Arnott ID, Landers CJ, Nimmo EJ et al. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype . Am J Gastroenterol 2004; 99: 2376-84.
7. Dubinsky MC, Lin YC, Dutridge D et al. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression . Am J Gastroenterol 2006;10:360-7.
8. Ferrante M, Henckaerts L, Joossens M et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour . Gut 2007; 56: 1394-403.
9. Forcione DG, Rosen MJ, Kisiel JB et al. Anti-Saccharomyces cerevisiae anti-body (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease . Gut 2004; 53: 1117-22.
10. Vasiliauskas EA, Plevy SE, Landers CJ et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup . Gastroenterology 1996; 110: 1810-9.
11. Austin GL, Shaheen NJ, Sandler RS. Positive and negative predictive values: use of inflammatory bowel disease serologic markers . Am J Gastroenterol 2006;10:413-6.
12. Rutgeerts P, Vermeire S. Clinical value of the detection of antibodies in the serum for diagnosis and treatment of inflammatory bowel disease . Gastroenterology 1998; 115: 1006-9.
13. Peyrin-Biroulet L, Standaert-Vitse A, Branche J et al. IBD serological panels: facts and perspectives . Inflamm Bowel Dis 2007; 13: 1561-6.
14. Papp M, Norman GL, Altorjay I et al. Utility of serological markers in inflammatory bowel diseases: gadget or magic? World J Gastroenterol 2007; 13: 2028-36.
15. Reese GE, Constantinides VA, Simillis C et al. Diagnostic precision of anti- Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease . Am J Gastroenterol 2006; 101: 2410-22.
16. Mow WS, Vasiliauskas EA, Lin YC et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease . Gastroenterology 2004; 126: 414-24.
17. Dotan N, Altstock RT, Schwarz M et al. Anti-glycan antibodies as biomarkers for diagnosis and prognosis . Lupus 2006; 15: 442-50.
18. Dotan I, Fishman S, Dgani Y et al. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease . Gastroenterology 2006; 131: 366-78.
19. Silverberg MS, Satsangi J, Ahmad T et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology . Can J Gastroenterol 2005; 19 (Suppl A): 5-36.
20. Quinton JF, Sendid B, Reumaux D et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role . Gut 998;42:788-91.
21. Peeters M, Joossens S, Vermeire S et al. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease . Am J Gastroenterol 2001; 96: 30-4.
22. Sandborn WJ, Lofus EV Jr, Colombel JF et al. Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease . Inflamm Bowel Dis 2001; 7: 192-201.
23. Vermeire S, Joossens S, Peeters M et al. Comparative study of ASCA (anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease . Gastroenterology 2001; 120: 827-33.
24. Vasiliauskas EA, Kam LY, Karp LC et al. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 2000;47:487-96.
25. Vermeire S, Peeters M, Vlietinck R et al. Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families . Inflamm Bowel Dis 2001; 7: 8-15.
26. Harrer M, Reinisch W, Dejaco C et al. Do high serum levels of anti-Saccharomyces cerevisiae antibodies result from a leakiness of the gut barrier in Crohn's disease? Eur J Gastroenterol Hepatol 2003; 15: 1281-5.
27. Israeli E, Grotto I, Gilburd B et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease . Gut 2005; 54: 1232-6.